Co-Diagnostics earnings release, August 13, 2026

Co-Diagnostics, Inc. (CODX) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Co-Diagnostics

Reports Second Quarter 2026 Financial Results

Advancing

Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion

Strengthening

Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and

AI-Enabled Capabilities

SALT

LAKE CITY, August 13, 2026 – Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx,” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the second quarter ended June 30, 2026.

Second

Quarter 2026 Business Highlights:

“Our second quarter marked a period of meaningful operational progress for Co-Diagnostics, as years of investment across our platform are illustrated by these tangible milestones,” said Dwight Egan, Chief Executive Officer of Co-Diagnostics. “This progress was reflected across our regulatory, clinical and commercial priorities, including expanding our tuberculosis program in India and strengthening our international manufacturing and commercialization capabilities. More recently, we built on that momentum by submitting our FDA 510(k) application for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® instrument.

Together, these milestones reinforce that we are executing against our strategic priorities and advancing the platform toward commercialization.”

Mr.

Egan continued, “What differentiates Co-Diagnostics is that we have never viewed our opportunity as simply developing another diagnostic test. We have built an integrated molecular diagnostics platform that combines instrumentation, assays, cloud connectivity and artificial intelligence, along with manufacturing, and global commercial infrastructure into a scalable ecosystem. As we continue to advance regulatory milestones and expand deployment across international markets, we believe this strategy has the potential to create long-term value for our shareholders.”

Second

Quarter 2026 Financial Results:

Recent

Developments:

Conference

Call and Webcast:

Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.

The conference call and webcast will be available via:

Webcast: ir.co-dx.com on the

Events & Webcasts page, or accessible directly here

Conference

Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)

The call will be recorded and later made available on the Company’s website.

*The

Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) has not been cleared or authorized by the FDA, is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About

Co-Diagnostics, Inc.

Co-Diagnostics,

Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.

The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules

(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform

(subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Non-GAAP

Financial Measures:

This press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income

(loss) adjusted for depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration, and realized gain (loss) on investments. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company’s management uses this non-GAAP measure to compare the Company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable

GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.

Forward-Looking

Statements:

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Product revenue166,131162,910
Total revenue166,131162,910
Cost of revenue45,30332,106
Gross profit120,828130,804
Operating expensesSales and marketing466,681609,713
Operating expensesGeneral and administrative1,500,8032,599,982
Operating expensesResearch and development4,152,2874,687,459
Operating expensesDepreciation and amortization201,840291,414
Operating expensesTotal operating expenses6,321,6118,188,568
Operating expensesLoss from operations-6,200,783-8,057,764
Other income (expense), netInterest income, net17,49312,158
Other income (expense), netRealized gain on investments340,358
Other income (expense), netLoss on disposition of assets-9,004
Other income (expense), netGain (loss) on remeasurement of acquisition contingencies-29,17110,222
Other income (expense), netLoss on equity method investment in joint ventures-52,157-13,760
Other income (expense), netTotal other income (expense), net-63,835339,974
Other income (expense), netLoss before income taxes-6,264,618-7,717,790
Other income (expense), netIncome tax provision19,16812,327
Other income (expense), netNet loss-6,283,786-7,730,117
Other comprehensive lossChange in net unrealized gains on marketable securities, net of tax-196,585
Other comprehensive lossTotal other comprehensive loss$--196,585
Other comprehensive lossComprehensive loss-6,283,786-7,926,702
Loss per common share:Basic and Diluted-1.46-7
Weighted average shares outstanding:Basic and Diluted4,309,9971,103,614

Balance Sheet

June 30, 2026 — (Unaudited)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents3,649,63211,884,607
Current assetsAccounts receivable, net52,059190,375
Current assetsInventory, net841,669992,397
Current assetsIncome taxes receivable42544,559
Current assetsPrepaid expenses and other current assets648,673581,527
Current assetsTotal current assets5,192,45813,693,465
Current assetsProperty and equipment, net1,975,1112,272,098
Current assetsOperating lease right-of-use asset1,769,0111,207,453
Current assetsIntangible assets, net7,219,0007,219,000
Current assetsInvestment in joint ventures435,051350,569
Current assetsTotal assets16,590,63124,742,585
Current liabilitiesAccounts payable1,078,3801,878,225
Current liabilitiesAccrued expenses899,183865,301
Current liabilitiesOperating lease liability, current784,261662,258
Current liabilitiesContingent consideration liabilities, current72,927119,036
Current liabilitiesDeferred revenue28,64414,800
Current liabilitiesTotal current liabilities2,863,3953,539,620
Long-term liabilitiesOperating lease liability1,014,887574,301
Long-term liabilitiesTotal long-term liabilities1,014,887574,301
Long-term liabilitiesTotal liabilities3,878,2824,113,921
Stockholders’ equityCommon stock, $0.001 par value; 100,000,000 shares authorized; 5,040,580 shares issued and 4,878,957 shares outstanding as of June 30, 2026 and 2,256,654 shares issued and 2,095,031 shares outstanding as of December 31, 202570,48467,700
Stockholders’ equityTreasury stock, at cost; 161,623 shares held as of June 30, 2026 and December 31, 2025, respectively-15,575,795-15,575,795
Stockholders’ equityAdditional paid-in capital124,015,023116,510,298
Stockholders’ equityAccumulated deficit-95,797,363-80,373,539
Stockholders’ equityTotal stockholders’ equity12,712,34920,628,664
Stockholders’ equityTotal liabilities and stockholders’ equity16,590,63124,742,585
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.

Forward-looking statements can be identified by words such as “believes,” “expects,”

“estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or... (truncated)s they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include, but are not limited to, statements regarding: (i) the continued development, clinical evaluation, regulatory submission, clearance, authorization, and commercialization of the Co-Dx PCR platform and related tests; (ii) anticipated timing and progress of clinical studies and regulatory submissions; (iii) the Company’s ability to develop, scale, and commercialize its manufacturing capabilities, including through

CoSara and

CoMira and other third parties;

(iv) anticipated market opportunities and international expansion initiatives; (v) the expected capabilities, differentiation, and adoption of the Company’s platform technologies; and (vi) the Company’s strategic, operational, and growth initiatives generally. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.

These risks and uncertainties include, among others, risks relating to the timing and outcome of FDA and other regulatory review processes; the possibility that clinical or analytical data may not support regulatory clearance, authorization or commercialization; the Company’s ability to successfully complete product development, manufacturing scale-up and commercialization activities; market acceptance and adoption of the Company’s products and technologies; the Company’s dependence on joint ventures, distributors, manufacturers and other third parties; risks associated with conducting business and obtaining regulatory approvals in international markets; the Company’s ability to obtain additional capital when needed and maintain sufficient liquidity to execute its business plans; and competitive and technological developments.

Actual results may differ materially from those contemplated or anticipated by such forward-looking statements.

Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any regulatory submission, authorization, commercialization milestone, manufacturing initiative, strategic collaboration, or market opportunity will occur on the timelines anticipated by the Company, or at all, due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission

(SEC) on March 31, 2026, and in our other filings with the SEC.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by applicable law.

Company

Contact:

Andrew

Benson

Head of Investor Relations

+1

801.438.1036 investors@codiagnostics.com

Investor

Contact:

Valter

Pinto, Managing Director

KCSA

Strategic Communications

+1

212.896.1254

CODX@KCSA.com

Media

Contact:

Jennifer

Webb

ColtrinMethod

PR jcoltrin@coltrinmethodpr.com

CO-DIAGNOSTICS,

INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Co-Diagnostics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.